S
Sonja Henne
Researcher at Ludwig Maximilian University of Munich
Publications - 2
Citations - 343
Sonja Henne is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Rifampicin & Ethambutol. The author has an hindex of 2, co-authored 2 publications receiving 265 citations.
Papers
More filters
Journal ArticleDOI
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
Martin J. Boeree,Norbert Heinrich,Rob E. Aarnoutse,Andreas H. Diacon,Rodney Dawson,Sunita Rehal,Gibson S. Kibiki,Gavin J. Churchyard,Gavin J. Churchyard,Ian Sanne,Nyanda E. Ntinginya,Lilian T. Minja,Robert D Hunt,Salome Charalambous,Madeleine Hanekom,Hadija H. Semvua,Stellah G. Mpagama,Christina Manyama,Bariki Mtafya,Klaus Reither,Klaus Reither,Robert S. Wallis,Amour Venter,Kim Narunsky,Anka Mekota,Sonja Henne,Angela Colbers,Georgette Plemper van Balen,Stephen H. Gillespie,Patrick P. J. Phillips,Michael Hoelscher +30 more
TL;DR: A dose of 35 mg/kg rifampicin was safe, reduced the time to culture conversion in liquid media, and could be a promising component of future, shorter regimens for the treatment of tuberculosis.
Journal ArticleDOI
Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients
Norbert Heinrich,Rodney Dawson,Jeannine Du Bois,Kim Narunsky,Gary Horwith,Andrew J. Phipps,Carol A. Nacy,Rob E. Aarnoutse,Martin J. Boeree,Stephen H. Gillespie,Amour Venter,Sonja Henne,Andrea Rachow,Patrick P. J. Phillips,Michael Hoelscher,Andreas H. Diacon +15 more
TL;DR: SQ109 alone or with rifampicin was safe over 14 days and did not appear to be active alone or to enhance the activity of rifampsicin during the 14 days of treatment.